The compound TC-2153 inhibits the negative effects of a protein called STtriatal-enriched tyrosine phosphatase (STEP), which is key to regulating learning and memory. As such it has potential as a therapeutic agent for Alzheimer's disease. Now, researchers at Yale School of Medicine have shown that the drug, found through screening thousands of molecules, reverses the brain deficits of Alzheimer’s disease in a mouse model of the disease. “Decreasing STEP levels reversed the effects of Alzheimer’s disease in mice,” explains Yale's Paul Lombroso. "The small molecule inhibitor is the result of a five-year collaborative effort to search for STEP inhibitors," said Lombroso. "A single dose of the drug results in improved cognitive function in mice. Animals treated with TC compound were indistinguishable from a control group in several cognitive tasks."
Murine Alzheimer's model